Hierarchical Affinities and a Bipartite Interaction Model for Estrogen Receptor Isoforms and Full-length Steroid Receptor Coactivator (SRC/p160) Family Members*

Nuclear receptor (NR)-mediated transcription is driven by dynamic multiprotein coactivator complexes, the composition of which is thought to determine the biological activity of NRs at specific promoters. The extent to which NRs discriminate between a spectrum of potential binding partners is intuitively a function of the inherent affinities of these individual interactions. Using real time interaction analysis with BIAcore, we evaluated the affinities and kinetics of the interactions of full-length members of the SRC/p160 coactivator family with estrogen receptor α (ERα) and ERβ bound to a variety of ligands. We substantiate that 17β-estradiol enhances the affinity of ER-SRC/p160 interactions, whereas 4(OH)-tamoxifen, raloxifene, and ICI-182,780 inhibit these interactions. We show that a well defined, ER isoform-specific hierarchy governs the association of liganded ERs with full length SRC/p160 family members. Moreover, our data indicate that the interaction affinities of the full-length SRC/p160s with ERs are significantly higher then those of the NR interaction domains of the same coactivators, indicating that portions of coactivator molecules distinct from NR interaction domains might participate in receptor-coactivator complex formation. Finally, the interaction kinetics of SRC/p160s with ERs are consistent with a bipartite model, involving initial rapid formation of an unstable intermediate complex, and a subsequent slower reaction leading to its stabilization. We interpret our results as evidence that hierarchical coactivator interaction affinities are an important source of diversity in NR-mediated signaling and that the complexity of receptor-coactivator cross-talk might be best understood in the context of full-length molecules.

[1]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[2]  K. Horwitz,et al.  Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer , 2000, Steroids.

[3]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Edwards,et al.  The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.

[5]  B. Komm,et al.  Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. , 2001, Biochemistry.

[6]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[7]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[8]  N. McKenna,et al.  Distinct steady-state nuclear receptor coregulator complexes exist in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[10]  B. O’Malley,et al.  Phosphorylation of Steroid Receptor Coactivator-1 , 2000, The Journal of Biological Chemistry.

[11]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[12]  J. Wong,et al.  p300 Requires Its Histone Acetyltransferase Activity and SRC-1 Interaction Domain To Facilitate Thyroid Hormone Receptor Activation in Chromatin , 2000, Molecular and Cellular Biology.

[13]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[14]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[15]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[16]  M. Lazar,et al.  The DRIP Complex and SRC-1/p160 Coactivators Share Similar Nuclear Receptor Binding Determinants but Constitute Functionally Distinct Complexes , 2000, Molecular and Cellular Biology.

[17]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[18]  K. Yamamoto,et al.  An Additional Region of Coactivator GRIP1 Required for Interaction with the Hormone-binding Domains of a Subset of Nuclear Receptors* , 1999, The Journal of Biological Chemistry.

[19]  H. Erdjument-Bromage,et al.  A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.

[20]  C. Lyttle,et al.  A Transcriptional Coactivator, Steroid Receptor Coactivator-3, Selectively Augments Steroid Receptor Transcriptional Activity* , 1998, The Journal of Biological Chemistry.

[21]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[22]  B. O’Malley,et al.  Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[24]  R. Roeder,et al.  Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[26]  R. Darnell,et al.  Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. , 2000, Molecular cell.

[27]  O. Hermanson,et al.  Nuclear receptor coregulators: multiple modes of modification , 2002, Trends in Endocrinology & Metabolism.

[28]  Donald P. McDonnell,et al.  The Opposing Transcriptional Activities of the Two Isoforms of the Human Progesterone Receptor Are Due to Differential Cofactor Binding , 2000, Molecular and Cellular Biology.

[29]  M. Parker,et al.  Molecular Determinants of the Estrogen Receptor-Coactivator Interface , 1999, Molecular and Cellular Biology.

[30]  C. Glass,et al.  Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators , 1998, Nature.

[31]  P. Chambon,et al.  Crystal structure of the human RXRα ligand‐binding domain bound to its natural ligand: 9‐cis retinoic acid , 2000 .

[32]  R. Roeder,et al.  The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.